Unveiling the pharmacological potential of plant triterpenoids in breast cancer management: an updated review.
Shaza H AlyAbdullah M M ElbadryAhmed S DoghishHeba A S El-NasharPublished in: Naunyn-Schmiedeberg's archives of pharmacology (2024)
Breast cancer is the most prevalent type of cancer, the fifth leading cause of cancer-related deaths, and the second leading cause of cancer deaths among women globally. Recent research has provided increasing support for the significance of phytochemicals, both dietary and non-dietary, particularly triterpenoids, in the mitigation and management of breast cancer. Recent studies showed that triterpenoids are promising agents in the treatment and inhibition of breast cancer achieved through the implementation of several molecular modes of action on breast cancer cells. This review discusses recent innovations in plant triterpenoids and their underlying mechanisms of action in combating breast cancer within the timeframe spanning from 2017 to 2023. The present work is an overview of different plant triterpenoids with significant inhibition on proliferation, migration, apoptosis resistance, tumor angiogenesis, or metastasis in various breast cancer cells. The anticancer impact of triterpenoids may be attributed to their antiproliferative activity interfering with angiogenesis and differentiation, regulation of apoptosis, DNA polymerase inhibition, change in signal transductions, and impeding metastasis. The present review focuses on several targets, mechanisms, and pathways associated with pentacyclic triterpenoids, which are responsible for their anticancer effects. We could conclude that natural triterpenoids are considered promising agents to conquer breast cancer.
Keyphrases
- breast cancer cells
- healthcare
- oxidative stress
- primary care
- squamous cell carcinoma
- breast cancer risk
- papillary thyroid
- endothelial cells
- cell death
- single molecule
- childhood cancer
- squamous cell
- vascular endothelial growth factor
- cell cycle arrest
- pregnant women
- signaling pathway
- quality improvement
- risk assessment
- combination therapy
- lymph node metastasis
- human health
- cell free
- pregnancy outcomes